Cyteir Therapeutics (CYT)
NASDAQ:CYT
US Market
Holding CYT?
Track your performance easily

Cyteir Therapeutics (CYT) Income Statement

24 Followers

Cyteir Therapeutics Income Statement

Last quarter (Q3 2023), Cyteir Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Cyteir Therapeutics's net income was $-3.53M. See Cyteir Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
---$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 18.15M$ -48.17M$ 42.26M$ 20.94M$ 16.11M
Operating Income
$ -38.25M$ -48.17M$ -42.26M$ -20.94M$ -16.11M
Net Non Operating Interest Income Expense
$ 4.38M----
Other Income Expense
$ -660.00K$ -2.11M$ -133.00K$ 120.00K$ 1.06M
Pretax Income
$ -33.21M$ -46.06M$ -42.13M$ -20.82M$ -15.04M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -33.21M$ -46.06M$ -42.13M$ -20.82M$ -15.04M
Basic EPS
$ -1.35$ -1.31$ -2.16$ -1.07$ -0.77
Diluted EPS
$ -0.95$ -1.31$ -2.16$ -1.07$ -0.77
Basic Average Shares
$ 142.63M$ 35.27M$ 19.50M$ 19.43M$ 19.43M
Diluted Average Shares
$ 142.63M$ 35.27M$ 19.50M$ 19.43M$ 19.43M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 18.15M$ -48.17M$ 42.26M$ 20.94M$ 16.11M
Net Income From Continuing And Discontinued Operation
$ -33.22M$ -46.06M$ -42.13M$ -20.82M$ -15.04M
Normalized Income
$ -7.23M--$ -20.82M$ -15.04M
Interest Expense
-----
EBIT
$ -34.75M$ -46.06M$ -42.13M$ -20.94M$ -16.11M
EBITDA
$ -34.15M$ -45.36M$ -41.63M$ -20.59M$ -15.89M
Currency in USD

Cyteir Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis